Active-ingredient Dossier

Lanreotide Acetate

Active-ingredient Dossier for Lanreotide Acetate (somatostatin analogue). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: MYTOLAC
Brand: SOMATULINE AUTOGEL
Brand: LACREO
Therapeutic area: Oncology

What is

Lanreotide Acetate Lanreotide Acetate is a somatostatin analogue.

Australian brands containing

Lanreotide Acetate — MYTOLAC — LANREOTIDE — SOMATULINE AUTOGEL — LACREO

Therapeutic areas

Lanreotide Acetate is registered in oncology, with 4 brands containing this ingredient on the ARTG.

Sponsor landscape

Lanreotide Acetate is marketed by three sponsors: Sun Pharma, Amdipharm Mercury, and Ipsen.

PBS and regulatory activity

One brand containing Lanreotide Acetate has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome is dated 1 July 2024, with three brands having PBAC outcomes on record.